biomimesys_liver Archives

Biomimesys

Feedback of Rania’s internship about the development of primary human hepatocyte model in biochip microfludic system

This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…

By Méryl Roudaut, 6 daysSeptember 28, 2023 ago

Biomimesys

Collaboration with CANTHER about breast cancer metastasis presented @EACR2023

Julien Cicero, with whom we are collaborating about the study of breast cancer metastasis mechanisms, was proud to present his PhD work during the last EACR conference. It was held in Torino (Italy) last month, during which Julien could discuss with cancer researchers from all around the world. His poster Read more…

By Elodie Vandenhaute, 3 monthsJuly 18, 2023 ago

Biomimesys

Meet HCS PHARMA at Forum Labo!

We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…

By Rita Hien, 6 monthsMarch 24, 2023 ago

Biomimesys

Happy World Organoid Research Day!

Organoids are three-dimensional structures made of cells, which can be derived from stem cells to mimic the structure and function of real organs. They are useful tools for studying human development, disease modeling, drug screening, and personalized medicine. Recent advancements in organoid research have focused on improving their complexity and Read more…

By Méryl Roudaut, 7 monthsMarch 22, 2023 ago

biomimesys_liver

Rania joins us to work on a Liver Biochip system

After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular carcinoma cell line) in Biochip, the project continue with Rania Chibani, who has joined us for a Read more…

By Méryl Roudaut, 7 monthsMarch 7, 2023 ago

Biomimesys

Feedback to ESTIV2022 congress (European Society of Toxicology In Vitro)

The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in vitro modeling. After a nice opening ceremony with a flamenco show, the scientific program begun Read more…

By Véronique De Conto, 10 monthsDecember 6, 2022 ago

Biomimesys

We are happy to give a presentation at ESTIV congress in Barcelona (21-25 November 2022)

Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…

By Méryl Roudaut, 11 monthsNovember 18, 2022 ago

Biomimesys

Welcome to Gaspard in HCS Pharma

We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…

By Elodie Vandenhaute, 12 monthsOctober 18, 2022 ago

Biomimesys

BIOMIMESYS® Liver for 3D in vitro models : applications and examples

3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). In this webinar we will focus on BIOMIMESYS® Liver and will discuss about its different applications. Read more…

By Grégory MAUBON, 1 yearJune 10, 2022 ago

Biomimesys

Human liver organoids and disease models, it’s time to use a more realistic ECM

The current hiPSC-derived models are adapted to reproduce diseases of genetic origin in two dimensions and have allowed in recent years to model diseases by using hepatocyte-like-cells (HCL) such as: Alpha1-antitrypsin (A1AT) deficiency (Tafaleng et al., 2015) Familial transthyretin-related amyloidosis (ATTR) (Isono et al., 2014) Glycogen storage deficiency (Satoh et Read more…

By Méryl Roudaut, 1 yearMay 24, 2022 ago

Biomimesys

Webinar “BIOMIMESYS® Liver for 3D in vitro models : applications and examples”

When Tuesday, May 31, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 2, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, using zoom.us and live on Youtube What 3D cell culture systems have recently emerged as Read more…

By Méryl Roudaut, 1 yearMay 10, 2022 ago

Biomimesys

Cellular structures in BIOMIMESYS® hydroscaffold using Scanning electron microscopy (SEM): example of liver cells

Scanning Electron Microscopy (EM) has been an indispensable tool for Biological sciences. A great challenge was propelled by the need to find methods to better preserve and analyze structures at a state closest to the native state. With BIOMIMESYS® hydroscaffold technology, we have developed a new method to use SEM Read more…

By Zied Souguir, 2 yearsMarch 17, 2022 ago

Biomimesys

A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening

The current hiPSC-derived models are adapted to reproduce diseases of genetic origin. However, the current two-dimensional HLC (hepatocyte like-cells) model has an immature liver phenotype that is more is closer to a perinatal liver. Furthermore, it does not take into account the complexity of the tissues and the extracellular environment Read more…

By Méryl Roudaut, 2 yearsMarch 15, 2022 ago

Biomimesys

Poster – A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of Read more…

By Grégory MAUBON, 2 yearsMarch 15, 2022 ago

Biomimesys

Importance of the liver extracellular matrix in the development of NASH/ASH

The extracellular matrix (ECM) is a non-cellular component of tissues and organs. It is mainly composed of structural elements (proteoglycans collagens, elastin) and cell adhesion proteins such as fibronectin and laminins. The ECM forms a complex structure with physical properties (elasticity, tensile and compression strength), which provides physical support for Read more…

By Méryl Roudaut, 2 yearsMarch 1, 2022 ago

Application Notes

Maintain CYP activity and inducibility with BIOMIMESYS® Liver

A relevant liver in vitro model should display CYP inducibility that mimics in vivo metabolic responsiveness to known modulators. This response of CYPs to induction is a critical parameter for predicting adverse drug reactions.

By Grégory MAUBON, 2 yearsDecember 7, 2021 ago

Application Notes

Maintain hepatocyte functions with BIOMIMESYS® Liver

Maintaining the basal characteristics of primary hepatocytes and HepG2 allows performing metabolic studies. The functional instability of hepatocytes in 2D culture results in a rapid decrease in specific metabolic pathways (Figure 1). Cell culture in BIOMIMESYS® Liver shows higher metabolic characteristics of hepatocytes compared to a culture in 2D, such Read more…

By Grégory MAUBON, 2 yearsDecember 3, 2021 ago

Application Notes

Increase culture time in BIOMIMESYS® Liver

BIOMIMESYS® Liver recreates the complex cellular microenvironment of the liver to extend longevity and functionality of hepatocytes in culture: The life of human primary hepatocytes grown in a 2D sandwich is low, 3-10 days (1) and is accompanied by dedifferentiation, leading to the loss of their functions. In 2D culture, Read more…

By Grégory MAUBON, 2 yearsNovember 11, 2021 ago

Application Notes

Allows hepatotoxicity studies with BIOMIMESYS® Liver

Hepatotoxicity testing in animals predicts only 50% of liver damage observed in clinical context, in part, because of difference in inter-species hepatic metabolism (1). Therefore, a relevant in vitro model mimicking the micro-environment of the human liver for maintaining and promoting hepatocyte functions, is needed for a better hepatotoxicity prediction Read more…

By Grégory MAUBON, 2 yearsNovember 5, 2021 ago

Biomimesys

October is the Breast Cancer Awareness Month – what’s new in HCS Pharma?

As you might know, October is the Breast Cancer Awareness Month, an annual campaign to raise awareness about the impact of breast cancer. Research is the key tool to fight this disease and we are very happy to collaborate with amazing research teams in this fight. Since last year, our Read more…

By Grégory MAUBON, 2 yearsOctober 12, 2021 ago

Biomimesys

We will present our work about the generation of functional human liver organoids with BIOMIMESYS® in CNRS thematic school

This week we will present at the thematic school “From 3D culture to the organoid: multidisciplinary research” organised by the Institute of Biological Sciences of CNRS (France) in Strasbourg. Study director Méryl Roudaut will talk about the generation of functional human liver organoids using hiPSC and our innovative 3D cell Read more…

By Grégory MAUBON, 2 yearsSeptember 14, 2021 ago

Biomimesys

Join us today at BIO-Asia Taiwan online exhibition!

Today is the opening of the virtual part of 2021 BIO-Asia Taiwan and we are happy to welcome you on our booth (R332) to present our latest innovations with BIOMIMESYS® for liver organoids. This event is organized by Taiwan Bio Industry Organization and Chan Chao International Co. It gathers over Read more…

By Grégory MAUBON, 2 yearsJuly 19, 2021 ago

Biomimesys

Meryl’s presentation at 17th ISVHLD GHS 2021 about liver organoids in BIOMIMESYS®

Our project leader Dr Meryl Roudaut was invited to present at the last ISVHLD congress, the Global Hepatitis Summit, in Taiwan. The theme of the summit, “Evolution and Revolution of Viral Hepatitis and Liver Disease”, was perfect to talk about the use of BIOMIMESYS® product to overcome the limitations of Read more…

By Grégory MAUBON, 2 yearsJuly 15, 2021 ago